Doctors Advocate Renaming PCOS to PMOS to Reflect Systemic Nature
Medical experts and the World Health Organization are advocating for renaming Polycystic Ovarian Syndrome (PCOS) to Polyendocrine Metabolic Ovarian Syndrome (PMOS). This change aims to better reflect the condition's full scope, which affects an estimated 10 to 13 percent of women of reproductive age globally. Experts argue that the previous name misleadingly emphasized ovarian cysts, which are not always present, thereby obscuring the broader metabolic and endocrine impacts of the disorder. Dr. Alla Vash-Margita from Yale University highlights that the condition is linked to insulin resistance, type 2 diabetes, cardiovascular disease, and mental health issues, rather than just reproductive symptoms. The proposed renaming is intended to reduce stigma, facilitate earlier and more accurate diagnoses, and encourage a holistic treatment approach across various medical specialties. By shifting the focus from solely ovarian issues to a systemic metabolic perspective, health professionals hope to improve patient awareness and ensure comprehensive care for those affected by this complex condition.
Editorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page itself is projected from evidence records.
- Current automated evidence projection